Botulinum toxin type A

Generic Name: Botulinum toxin type A

Brand Names: Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva

Drug Type: Biotech

Chemical Formula: -

CAS Number: 93384-43-1

Unique Ingredient Identifier: 0A6JH35GMQ

Background: In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other condit...

Indication: Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.
...

Associated Conditions: Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis

Associated Therapies: -

Clinical Trials

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

Phase 2

Recruiting

Conditions: Urologic Diseases
Overactive Bladder Syndrome
Urinary Incontinence
Overactive Bladder

Interventions: Drug: OnabotulinumtoxinA

First Posted Date: 2023-05-30

Last Posted Date: 2024-07-03

Lead Sponsor: Northwestern University

Target Recruit Count: 80

Registration Number: NCT05878951

Locations: 🇺🇸
Northwestern Medicine, Chicago, Illinois, United States

Assessment of Botulinum Toxin Injection for Treatment of Temporomandibular Joint Dislocation

Not Applicable

Recruiting

Conditions: Subluxation of Temporomandibular Joint
Dislocation of Temporomandibular Joint TMJ

Interventions: Drug: Botulinum toxin type A

First Posted Date: 2023-05-18

Last Posted Date: 2023-05-22

Lead Sponsor: Cairo University

Target Recruit Count: 28

Registration Number: NCT05863286

Locations: 🇪🇬
Faculty of Dentistry, Cairo university, Cairo, Elmanial, Cairo, Egypt

Efficacy of Prabotulinum and Onabotulinum Toxin-A for Facial Wrinkles

Phase 4

Completed

Conditions: Face
Rejuvenation
Skin Fold

Interventions: Drug: Onabotulinum toxin A
Drug: Prabotulinumtoxin A

First Posted Date: 2023-05-03

Last Posted Date: 2023-05-03

Lead Sponsor: Instituto de Oftalmología Fundación Conde de Valenciana

Target Recruit Count: 26

Registration Number: NCT05840445

Locations: 🇲🇽
Institute of Ophthalmology, Conde de Valenciana Foundation, Mexico, City, Mexico City, Mexico
🇲🇽
Instituto de Oftalmología, Mexico City, Mexico

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

Early Phase 1

Completed

Conditions: Rhytides

Interventions: Drug: PrabotulinumtoxinA-Xvfs
Drug: OnabotulinumtoxinA

First Posted Date: 2023-04-11

Last Posted Date: 2024-03-13

Lead Sponsor: Lupo Center for Aesthetic and General Dermatology

Target Recruit Count: 10

Registration Number: NCT05807412

Locations: 🇺🇸
Lupo Center for Aesthetic and General Dermatology, New Orleans, Louisiana, United States

Peripheral TMD Pain Mechanisms and the Effect by Botulinum Toxin A

Phase 2

Recruiting

Conditions: Temporomandibular Disorders

Interventions: Drug: Isotonic saline 0,9%
Drug: Botulinum toxin type A

First Posted Date: 2023-02-09

Last Posted Date: 2024-10-08

Lead Sponsor: Karolinska Institutet

Target Recruit Count: 40

Registration Number: NCT05720065

Locations: 🇸🇪
Department of Dental Medicine, Karolinska Institutet, Huddinge, Stockholm, Sweden

Wumeiwan Jiawei Fang Use in Patients With Blepharospasm

Phase 2

Recruiting

Conditions: Dry Eye Syndromes
Meige Syndrome
Blepharospasm
Hyperactivity

Interventions: Drug: Wumeiwan Jiawei Fang
Drug: botulinum toxin A

First Posted Date: 2022-11-16

Last Posted Date: 2022-11-17

Lead Sponsor: China Academy of Chinese Medical Sciences

Target Recruit Count: 80

Registration Number: NCT05618470

Locations: 🇨🇳
Eye Hospital, China Academy of Chinese Medical Sciences；GuangAnmen Hospital, China Academy of Chinese Medical Sciences；XiYuan Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China